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Purpose: We evaluated the effects of device guided, slow-paced respiration on
urgency associated urinary symptoms, perceived stress and anxiety, and auto-
nomic function in women with overactive bladder syndrome.
Materials and Methods: We performed a randomized, parallel group trial of
slow-paced respiration to improve perceived stress and autonomic dysfunction as
potential contributors to overactive bladder. Ambulatory women who reported at
least 3 voiding or incontinence episodes per day associated with moderate to
severe urgency were randomized to use a portable biofeedback device to practice
daily, slow, guided breathing exercises or a control device which appeared
identical and was reprogrammed to play music without guiding breathing.
During 12 weeks we evaluated changes in urinary symptoms by voiding diaries,
perceived stress and anxiety by validated questionnaires, and autonomic func-
tion by heart rate variability and impedance cardiography.
Results: In the 161 randomized participants, including 79 randomized to paced
respiration and 82 randomized to the control group, the average  SD baseline
frequency of voiding or incontinence associated with moderate to severe urgency
was 6.9  3.4 episodes per day. Compared to controls the participants random-
ized to paced respiration demonstrated greater improvement in perceived stress
(average Perceived Stress Scale score decrease 2.8 vs 1.1, p[0.03) but not in
autonomic function markers. During 12 weeks the average frequency of voiding
or incontinence associated with moderate to severe urgency, which was the study
primary outcome, decreased by a mean of 0.9  3.2 episodes per day but no
significant between group difference was detected.
Conclusions: Among women with overactive bladder slow-paced respiration was
associated with a modest improvement in perceived stress during 12 weeks.
However, it was not superior to a music listening control for reducing urinary
symptoms or changing autonomic function.
Key Words: urinary bladder, overactive; breathing exercises; relaxation
therapy; stress, psychological; autonomic nervous system
OVERACTIVE bladder, a syndrome char-
acterized by strong recurrent urges to
urinate (ie urgency), increased fre-
quency of daytime and nighttime uri-
nation, and in some patients urgency
incontinence, affects up to 1 of 5
women and can have a major impact
on functioning and quality of life.1,2
Currently the most widely used
treatment of OAB is antimuscarinic
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medications, which are modestly effective in
decreasing urgency associated voiding but associ-
ated with side effects3 and a high discontinuation
rate.4 While behavioral management techniques
such as bladder retraining are better tolerated,
many patients have difficulty practicing them
effectively without intensive training from
specialized practitioners.5 As a result, alternate
treatment strategies are needed which are safer
and more accessible.
Epidemiological studies have documented strong
associations of perceived stress and anxiety with
urinary urgency in women with OAB, including an
increased risk of new onset OAB among those with
high baseline levels of stress or anxiety.6,7 Clinical
studies have also indicated that patients with OAB
tend to have abnormalities in peripheral autonomic
function, which are in turn associated with clinical
anxiety disorders.8e10 These findings have gener-
ated interest in identifying alternate therapeutic
approaches directed at improving perceived stress,
anxiety and associated autonomic dysfunction as
potential contributors to OAB.11,12
One such potential therapy is slow-paced respi-
ration, a behavioral technique involving slowing the
respiratory rate to below 10 breaths per minute
with the goal of improving perceived stress, anxiety
and autonomic balance. Slow breathing exercises
are already used to a limited extent in urge sup-
pression techniques for OAB, in that patients are
told to take slow, deep breaths upon experiencing an
urge to urinate to distract themselves from the
bladder sensation. However, to our knowledge prior
research has not determined whether slow breath-
ing may be useful, not just as an ad hoc response to
isolated episodes of urgency but also as a regular
program of breathing exercises to alter underlying
susceptibility to OAB.
MATERIALS AND METHODS
The CURE (Controlling Urgency through Relaxation Ex-
ercises) study is a randomized, parallel group trial of de-
vice guided, slow-paced respiration in women with OAB.
Participants were ambulatory women recruited from 2014
to 2017 at 2 study clinics in San Francisco and Oakland,
California affiliated with UCSF (University of California-
San Francisco). Women were eligible for study if they
documented an average of at least 3 voiding or inconti-
nence episodes per day associated with at least a moder-
ate sensation of urgency in a voiding diary13 and they
agreed to temporarily forego other clinical OAB
treatments.
Women were excluded if they reported a history of
pelvic cancer or irradiation, prior bladder surgery or other
pelvic surgery in the last 3 months, interstitial cystitis,
bladder or rectal fistula, a congenital urinary tract defect,
symptomatic pelvic organ prolapse, 3 or more recurrent
urinary tract infections per year or major neurological
conditions such as stroke or multiple sclerosis. Addition-
ally, women could not have evidence of hematuria or
infection on screening urinalysis, be pregnant or planning
pregnancy, or have a chronic pulmonary condition which
would interfere with slow breathing exercises. Women
receiving anxiolytics or antidepressants were required to
be on a steady dose for a month. No exclusions were made
for the use of b or a blocker, or agonist medication.
Although women engaged in practitioner administered
behavioral relaxation therapies were excluded from study,
participants were not precluded from using other informal
self-administered relaxation practices.
All participants provided written informed consent.
The study was approved by the UCSF Institutional Re-
view Board (No. 14-13319) and registered on Clin-
icalTrials.gov (NCT02202031).
Participants were randomly assigned in equal ratios to
the paced respiration or the control intervention by a
computer algorithm using randomly permuted block sizes
of 2, 4 and 6. Women assigned to paced respiration were
instructed to use the commercially available RESPeRATE
portable biofeedback device, which is currently approved
by the Food and Drug Administration for adjunctive
treatment of hypertension based on evidence that regular
use decreases high blood pressure attributable to excess
sympathetic tone.14e16 The device senses the respiratory
rate of the user using an elastic belt placed around the
chest and it plays musical tones synchronized to inspira-
tion and expiration. The device gradually increases the
interval between musical tones to guide the user in
slowing respiration and expiration. Consistent with hy-
pertension use, the CURE participants randomized to
paced respiration were instructed to practice slowing
respiration for a minimum of 15 minutes per day for 12
weeks.
To enable rigorous evaluation of efficacy participants
randomized to the control group were given an identically
appearing RESPeRATE device reprogrammed to play
quiet nonrhythmic music while monitoring spontaneous
breathing. They were also instructed to use it for a min-
imum of 15 minutes per day for 12 weeks. Participants
and study staff responsible for monitoring adherence were
aware of the intervention assignment.
Adherence to device use was recorded automatically
by the devices in each group. All participants also
received basic written information about behavioral self-
management strategies for OAB, including timed urina-
tion and urge suppression, consistent with usual first line
care.
OAB symptoms were assessed at baseline and 12
weeks using a validated 3-day voiding diary administered
in previous OAB trials.13 Participants recorded each time
that they experienced an urge to urinate, voided in the
toilet or leaked urine and they rated the severity of ur-
gency associated with each episode using a standardized
scale of none, mild, moderate or severe.17 Diary data were
abstracted by research staff blinded to the intervention
assignment. An OAB composite score was calculated
which assigned points to voiding and incontinence based
on associated urgency.17
Participants also completed structured item, validated
questionnaires of the severity or the impact of urinary
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symptoms at baseline and 12 weeks, including the
OAB-Q,18 the USIQ19 and the PPBC.20 Additional ques-
tionnaires were used to assess perceived stress and asso-
ciated anxiety symptoms at baseline and at 12 weeks,
including the Cohen PSS to assess subjective feelings and
thoughts related to perceived stress,21 the STAI trait
component to assess somatic anxiety22 and the anxiety
subscale of the HADS to assess cognitive anxiety.23
Table 1 shows score range and directionality.
Among participants enrolled in San Francisco resting
cardiac autonomic function was assessed by electrocardi-
ography derived heart rate variability and impedance
cardiography at baseline and 12 weeks. Standardized
procedures for these measurements were described pre-
viously.24 Briefly, while sitting in a quiet, ambient tem-
perature room, participants were outfitted with a
standard tetrapolar electrode system composed of 2 inner
electrodes placed at the xiphisternal joint and the base of
the neck with outer electrodes place 3 cm distal to the
inner electrodes. Participants were then asked to view a
neutral video for at least 5 minutes while resting mea-
surements were sampled at 1,000 Hz. Measurements
were stored using an MP150 data acquisition system
(Biopac).
To assess sympathetic autonomic activity measure-
ments focused on the PEP, that is the period from the
start of cardiac ventricular depolarization to aortic valve
opening. The PEP provides a measure of ventricle
contractility, which has been shown to be a relatively pure
measure of sympathetic activity since it occurs during
systole, when there are no parasympathetic influences on
the cardiac cycle. Increases in peripheral sympathetic
nervous system activity correspond to a shortening PEP.25
To assess parasympathetic activity analyses focused on
RSA. This is heart rate variability during the typical
respiratory cycle, which is measured by heart rate vari-
ability in the high frequency range, reflecting the amount
of influence of the cardiac vagus nerve with higher RSA
corresponding to greater peripheral parasympathetic ac-
tivity.26 Although to our knowledge there are no validated
thresholds to classify subjects with abnormal sympathetic
or parasympathetic tone based on the PEP or RSA, prior
studies have mentioned a mean  SE PEP of 102  4.1
and a mean RSA of 6.5  3.9 in healthy community
populations.27,28
Adverse events were assessed at 1, 6 and 12-week fol-
lowups by asking participants whether they had experi-
enced any negative change in health. Serious adverse
events were defined as death, hospitalization or disability.
The primary study outcome was the 12-week change in
the frequency of voiding or incontinence episodes associ-
ated with at least moderate urgency. Secondary outcomes
included the 12-week change in the frequency of voiding
or incontinence associated with severe urgency, urgency
type incontinence, daytime and nighttime voiding, the
OAB symptom composite score, and the OAB-Q, USIQ
and PPBC scores.
A sample size of 160 subjects (80 per group) was
selected to provide 80% power on 2-sided tests with a 5%
type I error to detect a between group difference of more
than 20% in the primary outcome in the paced respiration
group vs the control group. This assumed a mean 30%
reduction in outcome frequency among controls, a 0.59
correlation between baseline and followup, and a 15% loss
to followup.
Baseline characteristics of participants as well as
adherence to interventions at followup visits were exam-
ined with descriptive statistics. Between group differ-
ences in baseline characteristics were assessed using the
chi-square test for categorical variables and the
Kruskal-Wallis test for continuous variables. ANCOVA
models were developed to estimate least square mean
changes in all outcomes in each intervention group during
12 weeks and test for between group differences while
adjusting for baseline values. Change values were 98% to
99% winsorized if indicated by visual inspection of Q-Q
plots. Models examining intervention effects on auto-
nomic outcomes were further adjusted for diabetes mel-
litus, which was unequally distributed between the
groups at baseline in the subset of women who provided
autonomic data as well as information on b or a blocker,
agonist or sympathomimetic medication.
Only participants who provided 12-week data were
included in the initial intervention effects models. How-
ever, to examine the implications of missing data 15
multiple imputed data sets were created using the Mar-
kov chain Monte Carlo method29 and summary effect es-
timates with the SE were calculated using standard
methods for imputed data. All analyses were performed
with SAS, version 9.4.
RESULTS
A total of 833 women were contacted, of whom 631
completed screening and 161 were found eligible
and randomized, including 79 to paced respiration
and 82 to the control group (see figure). The most
common single reason for study ineligibility was
insufficient frequency of urgency associated urinary
symptoms. Five women (10%) assigned to paced
respiration and 6 (7%) who served as controls dis-
continued participation early.
At baseline participants reported an average of
6.9  3.4 moderate to severe urgency associated
voiding or incontinence episodes, 1.3  1.0
nocturnal voiding episodes and 1.3  2.0 urgency
incontinence episodes per day (table 1). Mean PSS
questionnaire scores were close to the threshold of
14 used to indicate increased perceived stress but
mean scores on other anxiety measures were below
standard thresholds of clinically significant anxiety.
No significant between group differences were
detected in outcome measures at baseline.
Of the 150 participants who completed the 12-
week visit those in the paced respiration and con-
trol groups practiced the assigned intervention an
average of 4.8 and 5.5 days per week, respectively,
at 12 weeks (table 2). On those days they practiced
an average of 16.8 and 16.4 minutes per day in the
paced respiration and control groups, respectively.
Participants in each group reported modest de-
creases in the frequency of OAB symptoms,
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Table 1. Baseline participant demographic and clinical characteristics by intervention assignment
Paced Respiration Music Control
p Value (chi-square
or Kruskal-Wallis test)
No. pts 79 82
Mean  age 60.4  11.4 61.7  10.9 0.42
No. race/ethnicity (%): 0.53
NonLatina Caucasian 40 (50.6) 49 (59.8)
Latina Caucasian 12 (15.2) 6 (7.3)
Asian/Asian American 8 (10.1) 6 (7.3)
African American 12 (15.2) 12 (14.6)
Mixed race 5 (6.3) 8 (9.8)
Unknown 2 (2.5) 1 (1.2)
No. self-reported general health (%): 0.29
Excellent 19 (24.1) 28 (34.1)
Very good 36 (45.6) 31 (37.8)
Good 22 (27.8) 18 (22.0)
Fair/poor 2 (2.5) 5 (6.1)
No. selected medication (%):
Diuretic (thiazide or other nonloop) 8 (16.7) 5 (8.3) 0.19
Sedative/hypnotics 1 (2.1) 2 (3.3) 0.69
Tricyclic antidepressants 4 (8.3) 3 (5.0) 0.48
Selective serotonin/norepinephrine reuptake inhibitors 9 (18.8) 11 (18.3) 0.96
Other antidepressants 2 (4.2) 1 (1.7) 0.43
b blockers 5 (6.3) 13 (15.9) 0.06
b agonists 0 (0.0) 1 (1.2) 0.33
a blockers 2 (2.5) 1 (1.2) 0.54
Sympathomimetics 2 (2.5) 1 (1.2) 0.54
No. parity (%): 0.30
0 19 (24.1) 19 (23.2)
1 or 2 35 (44.3) 28 (34.1)
3 or More 25 (31.6) 35 (42.7)
No. gynecologic history (%):
Postmenopausal 62 (78.5) 68 (82.9) 0.47
Oophorectomy 13 (16.5) 15 (18.3) 0.76
Hysterectomy 14 (17.7) 11 (13.4) 0.45
No. health related habits (%):
Current cigarette smoking 0 (0.0) 3 (3.7) 0.08
Weekly alcohol consumption 34 (43.0) 44 (53.7) 0.18
Mean  SD physical examination measures:
Body mass index (kg/m2) 27.8  5.8 28.4  7.7 0.97
Blood pressure (mm Hg):
Systolic 122.1  17.4 119.8  15.3 0.42
Diastolic 75.4  10.3 74.4  9.1 0.49
Median No. incontinence or voiding episodes/day (IQR): 6.7 (4.7, 9.3) 6.0 (4.0, 8.0) 0.16
At least severe urgency 2.3 (1.3, 4.0) 2.0 (0.7, 3.0) 0.09
Urgency 0.7 (0.0, 2.0) 0.7 (0.0, 1.7) 0.89
Daytime voiding regardless of urgency 9.3 (8.0, 11.7) 8.7 (7.3, 11.0) 0.29
Nighttime voiding regardless of urgency 1.0 (0.3, 2.0) 1.3 (0.7, 2.0) 0.23
OAB composite score* 28.0 (21.3, 34.7) 24.3 (20.0, 31.0) 0.16
Urinary symptom questionnaire scores:
Median OAB-Q (IQR)† 29.7 (21.2, 41.2) 30.0 (20.6, 38.8) 0.83
Mean  SD USIQ Severity Subscale‡ 58.5  14.5 58.5  11.7 0.79
Mean  SD USIQ Quality of Life Subscale‡ 24.6 19.4 21.9  15.4 0.69
Median Urogenital Distress Inventory-Short Form (IQR)§ 44.4 (33.3, 61.1) 44.4 (33.3, 55.6) 0.84
Median PPBC (IQR){ 3.0 (2.0, 3.0) 3.0 (2.0, 3.0) 0.87
Median stress þ anxiety questionnaire scores (IQR):
PSSk 14.0 (8.0, 20.0) 13.0 (9.0, 18.0) 0.41
STAI-Trait Component** 37.0 (31.0, 45.0) 35.5 (28.0. 44.0) 0.33
HADS-Anxiety Subscale†† 7.0 (4.0, 10.0) 6.0 (3.0, 9.0) 0.37
Mean  SD msec autonomic function parameters (range):‡‡
Pre-ejection period (msec) 117.1  14.8 (78.0, 144.6) 123.1  11.5 (102.4, 149.6) 0.16
Respiratory sinus arrhythmia (msec2) 5.7  1.6 (2.3, 9.4) 4.8  1.2 (1.7, 6.4) 0.052
* Calculated by assigning points for mild (1), moderate (2) and severe (3) urgency associated voiding and urgency incontinence (5 points each), and averaging across days.
† Scored from 0 to 100 with higher scores indicating greater OAB bother and impact.
‡ Scored from from 0 to 100, with higher scores indicating greater severity and impact of urinary symptoms.
§ Scored from 0 to 75 with higher scores indicating greater urogenital symptom bother.
{Scored using a 6-point Likert scale, with higher scores indicating greater perception of bladder-related problems.
k Scored from 0 to 40, with higher scores indicating greater perceived stress.
** Trait component scored from 20 to 80, with higher scores indicating greater somatic anxiety.
†† Scored from 0 to 21 with higher scores indicating greater cognitive anxiety.
‡‡ Collected at baseline among the 30 women in the paced respiration and 22 women in the music control group at the San Francisco site.
790 DEVICE GUIDED RESPIRATION AND OVERACTIVE BLADDER
Copyright © 2019 American Urological Association Education and Research, Inc. Unauthorized reproduction of this article is prohibited.
including voiding or incontinence episodes associ-
ated with at least moderate urgency, during the 12
weeks (table 3). However, no significant between
group differences were detected in a change in OAB
symptoms. Participants in each group also demon-
strated modest improvements in multiple urinary
symptom questionnaire scores during the 12 weeks
but the changes did not differ significantly between
the groups (table 3). Findings were not significantly
affected by analyses using multiple imputation to
account for missing data.
Average scores on perceived stress and anxiety
symptom questionnaires decreased modestly in the
2 groups during 12 weeks (table 4). Participants
CONSORT (Consolidated Standards of Reporting Trials) diagram of participant recruitment, randomization and followup
Table 2. Adherence to intervention practice by intervention
assignment and time point
Practice
Paced
Respiration
Music
Listening p Value
Mean  SD No. days/wk:
Wk 1 5.6  1.6 5.7  1.4 0.71
Wk 6 5.1  1.6 5.5  1.3 0.18
Wk 12 4.8  2.1 5.5  2.1 0.048
Mean  SD on practice days
(mins/day):
Wk 1 15.2  2.7 15.5  2.7 0.78
Wk 6 16.7  3.4 16.2  3.1 0.10
Wk 12 16.8  4.0 16.4  5.3 0.17
*Practice adherence assessed by reviewing downloaded RESPeRATE data among
participants confirmed to have received assigned intervention, including 77 women
in paced respiration group at week 1, 74 at week 6 and 74 at week 12, and in the
music listening group 79 at week 1, 78 at week 6 and 76 at week 12.
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assigned to slow-paced respiration demonstrated
greater improvements in PSS scores than those
assigned to music control but no other significant
between group differences were observed in the
change in anxiety or symptoms (table 4).
No significant within group changes in resting
parasympathetic or sympathetic function were
observed during 12 weeks in the 44 women who
underwent autonomic function assessments at
baseline and 12 weeks, including 25 in the paced
respiration group and 19 in the control group
(table 4). Additionally, no significant between group
differences were noted in autonomic function.
On safety assessments 30 women assigned to
paced respiration and 29 assigned to the control
group reported 1 or more adverse events (p[0.73).
There were no reports of serious adverse events or
of any adverse events directly attributable to study
interventions.
DISCUSSION
In this randomized trial women with OAB assigned
to practice daily slow, guided breathing exercises
reported greater improvement in perceived stress
during 12 weeks relative to that in the control group
which listened to music control. However, the
improved group did not show greater improvement
in the frequency of urgency associated voiding or
incontinence, in other OAB questionnaires or in
autonomic function. Although paced respiration has
been used successfully to treat other conditions
associated with high perceived stress and/or pe-
ripheral autonomic dysfunction, our findings do not
support paced respiration as a uniquely effective
treatment of OAB.
Slow breathing has already been incorporated to
a limited extent into conservative urge suppression
distraction and relaxation techniques to manage
acute urgency episodes in OAB cases. When feeling
Table 3. Average change in urinary symptom frequency and urinary symptom questionnaire scores in 12 weeks by intervention
assignment
Paced Respiration Music Control Between Group Difference
Mean (95% CI)* p Value Mean (95% CI)* p Value Mean (95% CI)* p Value
Diary urinary symptom frequency:
Incontinence or voiding episodes associated with at least moderate
urgency/day
e0.8 (e1.5, e0.1) 0.02 e1.1 (e1.7, e0.4) <.01 0.2 (e0.7, 1.2) 0.62
Incontinence or voiding episodes associated with severe urgency/day e0.9 (e1.3, e0.6) <0.01 e0.9 (e1.2, e0.5) <0.01 e0.1 (e0.6, 0.5) 0.77
Urgency incontinence episodes/day e0.6 (e0.8, e0.3) <0.01 e0.6 (e0.9, e0.4) <0.01 0.1 (e0.2, 0.4) 0.65
Daytime voiding episodes/day regardless of urgency e0.7 (e1.1, e0.3) <0.01 e0.8 (e1.2, e0.3) <0.01 0.1 (e0.6, 0.7) 0.82
Nighttime voiding episodes/night regardless of urgency e0.4 (e0.6, e0.2) <0.01 e0.3 (e0.4, e0.1) <0.01 e0.1 (e0.4, 0.1) 0.28
Total No. voiding episodes/day regardless of urgency e1.1 (e1.5, e0.6) <0.01 e1.0 (e1.5, e0.6) <0.01 0.0 (e0.7, 0.6) 0.92
Modified OAB symptom composite score† e3.2 (e4.9, e1.4) <0.01 e3.6 (e5.4, e1.8) <0.01 0.4 (e2.1, 2.9) 0.75
Urinary symptom questionnaire scores:
Overall OAB-Q e14.3 (e16.9, e11.7) <0.01 e15.5 (e18.0, e12.9) <0.01 1.2 (e2.5, 4.8) 0.54
OAB-Q bother subscale e19.2 (e22.5, e15.8) <0.01 e17.9 (e21.2, e14.6) <0.01 e1.3 (e6.0, 3.4) 0.60
OAB-Q health related quality of life subscale e12.8 (e15.4, e10.2) <0.01 e14.6 (e17.1, e12.1) <0.01 1.8 (e1.8, 5.4) 0.33
Severity USIQ subscale e13.9 (e17.1, e10.6) <0.01 e15.6 (e18.8, e12.3) <0.01 1.7 (e2.9, 6.3) 0.47
Health related quality of life USIQ subscale e10.2 (e13.2, e7.2) <0.0001 e12.4 (e15.3, e9.4) <0.0001 2.2 (e2.1, 6.4) 0.31
Urogenital Distress Inventory-Short Form e17.1 (e20.9, e13.4) <0.0001 e15.4 (e19.1, e11.6) <0.0001 e1.8 (e7.1, 3.5) 0.51
PPBC e0.9 (e1.1, e0.7) <0.0001 e0.7 (e1.0, e0.5) <0.0001 e0.1 (e0.4, 0.2) 0.36
* Least square mean estimates of change and 95% CI derived from ANCOVA models adjusted for baseline values.
† Calculated by assigning points per episode mild urgency associated voiding (1), moderate urgency associated voiding (2), severe urgency associated voiding (3) and urgency
incontinence (5 points each) per day and averaging across all diary days with 0 point for voiding episodes without urgency.
Table 4. Change in perceived stress, anxiety and depression measures, and sympathetic and parasympathetic autonomic function
markers in 12 weeks by intervention assignment
Paced Respiration Music Control Between Group Difference
Mean (95% CI)* p Value Mean (95% CI)* p Value Mean (95% CI)* p Value
Measures: <0.01
PSS e2.8 (e4.0, e1.7) e1.1 (e2.2, e0.0) 0.05 e1.7 (e3.3, e0.1) 0.03
STAI-Trait Component e2.9 (e4.3, e1.4) e2.4 (e3.8, e1.0) <0.01 e0.4 (e2.4, 1.6) 0.67
HADS-Anxiety Subscale† e1.4 (e1.9, e0.9) e0.7 (e1.2, e0.2) <0.01 e0.7 (e1.4, 0.1) 0.08
Markers:†
Pre-ejection period (msec) 0.34 (e20.2, 20.9) 0.97 e3.4 (e21.9, 15.1) 0.72 3.8 (e7.1, 14.6) 0.49
Respiratory sinus arrhythmia (msec2) e0.27 (e1.1, 0.6) 0.52 e0.4 (e1.1, 0.3) 0.27 0.14 (e0.3, 0.6) 0.56
* Least square mean estimates of change and 95% CIs derived from ANCOVA models and adjusted for baseline values.
† Estimated mean changes represent raw values and due to skewed distribution p values were derived from models using winsorized (98-99th percentile) values.
792 DEVICE GUIDED RESPIRATION AND OVERACTIVE BLADDER
Copyright © 2019 American Urological Association Education and Research, Inc. Unauthorized reproduction of this article is prohibited.
the urge to urinate, patients are often told to sit or
stand still, take deep, slow breaths and try to
distract themselves from the bladder sensation.
When combined with other behavioral modification
strategies, urge suppression appears moderately
effective in reducing OAB symptoms.30 However, to
our knowledge the breathing component of urge
suppression has not previously been studied apart
from other components of OAB self-management.
Slow-paced respiration has also been used to
manage other chronic conditions associated with
high levels of perceived stress or autonomic
dysfunction. In particular the RESPeRATE guided
breathing device is currently used for adjunctive
treatment of hypertension.14e16 However, in our
study we did not detect significant changes in
resting autonomic function associated with paced
respiration in women with OAB. A recent trial of
the RESPeRATE for a different indication (meno-
pause related vasomotor symptoms) also indicated
no significant effect on similar autonomic measures
in women.24
This research benefits from the rigorous time
equivalent control, the high retention rate and
objective confirmation of intervention adherence.
Nevertheless, several limitations should be noted.
1) Women were classified with OAB based on self-
reported history and urinalysis testing without
urodynamic or other clinical evaluation to further
characterize pathophysiology. 2) The change in
urinary symptoms was assessed by a voiding diary,
which can be associated with measurement error
despite its widespread use as an outcome measure
in OAB trials. 3) While the music listening inter-
vention was selected to rigorously control the time
and attention spent on paced respiration, it was also
an intervention with potential relaxing effects in its
own right, which could have a role in improving
participant perceived OAB symptoms. Conse-
quently study results should not be used to draw
conclusions about the effects of paced respiration vs
no intervention at all. 4) Autonomic measurements
were available only in the subset of participants
seen at the San Francisco clinic, which may have
limited our ability to detect changes in these out-
comes. 5) Additionally, participants with OAB were
not required to demonstrate clinically significant
perceived stress or anxiety, or abnormal autonomic
function at baseline, which may have resulted in
ceiling/floor effects for these outcomes.
CONCLUSIONS
The findings of this randomized trial indicate that
women with OAB who practice daily device guided,
paced respiration exercises may experience greater
improvement in perceived stress. However, they are
no more likely to report improvement in urgency
associated urinary symptoms than those who spend
equivalent time listening to music. While behavioral
relaxation based therapies may offer general bene-
fits for OAB, this study does not support unique
benefits of paced respiration for urgency associated
urinary symptoms.
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